216 related articles for article (PubMed ID: 25769985)
1. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?
Roobol MJ
Eur Urol; 2015 Sep; 68(3):363-4. PubMed ID: 25769985
[No Abstract] [Full Text] [Related]
2. Doing it right: how, not whether, to perform prostate-specific antigen screening.
Martin NE
Eur Urol; 2015 Sep; 68(3):361-2. PubMed ID: 25794459
[No Abstract] [Full Text] [Related]
3. First, do no harm.
Pimlott N
Can Fam Physician; 2012 Sep; 58(9):915. PubMed ID: 22972717
[No Abstract] [Full Text] [Related]
4. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Taneja SS
J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657
[No Abstract] [Full Text] [Related]
5. Managing localized prostate cancer in the era of prostate-specific antigen screening.
Brooks JD
Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
[TBL] [Abstract][Full Text] [Related]
6. The dilemmas of prostate cancer screening.
Hugosson J; Carlsson SV
Med J Aust; 2013 Jun; 198(10):528-9. PubMed ID: 23725256
[No Abstract] [Full Text] [Related]
7. Prostate cancer screening can save lives but it is too early for a national programme, study finds.
Sayburn A
BMJ; 2014 Aug; 349():g5055. PubMed ID: 25102993
[No Abstract] [Full Text] [Related]
8. The dilemmas of prostate cancer screening.
Del Mar CB
Med J Aust; 2013 Nov; 199(9):584. PubMed ID: 24182218
[No Abstract] [Full Text] [Related]
9. The dilemmas of prostate cancer screening.
Hugosson J; Carlsson SV
Med J Aust; 2013 Nov; 199(9):583-4. PubMed ID: 24182217
[No Abstract] [Full Text] [Related]
10. The dilemmas of prostate cancer screening.
Lawrentschuk N; Murphy DG; Costello AJ
Med J Aust; 2013 Nov; 199(9):583. PubMed ID: 24182216
[No Abstract] [Full Text] [Related]
11. The dilemmas of prostate cancer screening.
Haines IE
Med J Aust; 2013 Nov; 199(9):582-3. PubMed ID: 24182215
[No Abstract] [Full Text] [Related]
12. The dilemmas of prostate cancer screening.
McKenzie PR; Delahunt B; Kench JG
Med J Aust; 2013 Nov; 199(9):582. PubMed ID: 24182214
[No Abstract] [Full Text] [Related]
13. The dilemmas of prostate cancer screening.
Miklos GG
Med J Aust; 2013 Nov; 199(9):582. PubMed ID: 24182213
[No Abstract] [Full Text] [Related]
14. Re: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-Specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Taneja SS
J Urol; 2015 Aug; 194(2):393-4. PubMed ID: 26195364
[No Abstract] [Full Text] [Related]
15. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
McKenzie PR; Delahunt B; Kench JG; Sikaris KA
Pathology; 2014 Jan; 46(1):91-2. PubMed ID: 24300730
[No Abstract] [Full Text] [Related]
16. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
Zardawi IM
Pathology; 2014 Jan; 46(1):91. PubMed ID: 24300722
[No Abstract] [Full Text] [Related]
17. Should we screen for prostate cancer? A re-examination of the evidence.
Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
[No Abstract] [Full Text] [Related]
18. Use of Prostate-Specific Antigen Testing Is in the Eye of the Beholder.
Aaronson DS; Redberg RF
JAMA Intern Med; 2016 Apr; 176(4):547-8. PubMed ID: 26856746
[No Abstract] [Full Text] [Related]
19. Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performed.
Carter HB
Oncology (Williston Park); 2014 Feb; 28(2):155-6. PubMed ID: 24701706
[No Abstract] [Full Text] [Related]
20. The Era of Prostate-specific Antigen-based Personalized Prostate Cancer Screening Has Only Just Begun.
Schlomm T
Eur Urol; 2015 Aug; 68(2):214-5. PubMed ID: 25680240
[No Abstract] [Full Text] [Related]
[Next] [New Search]
